RD140 achieved ~89% ORR & MRD negativity rate in heavily pretreated, high-risk RRMM or plasma cell leukemia patients
“We are very pleased to present preliminary data from the first-in-human study of RD140 at this year’s IMS Annual Meeting. In patients with relapsed/refractory multiple myeloma (R/R MM) and plasma cell leukemia (PCL) — all triple-class exposed, mostly penta-exposed, and high-risk — RD140, leveraging its BCMA/GPRC5D dual-target design, achieved an objective response rate (ORR) of 88.9% and an exceptionally high MRD negativity rate, with no immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade observed. Of particular note, the FasT CAR-T rapid manufacturing platform enables cell manufacturing to be completed in just 3–4 days, significantly shortening the waiting time for patients and securing a valuable treatment window for more critically ill patients.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000